Cynosure Group LLC Reduces Stock Position in Repligen Co. (NASDAQ:RGEN)

Cynosure Group LLC cut its position in Repligen Co. (NASDAQ:RGEN) by 4.9% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,877 shares of the biotechnology company’s stock after selling 147 shares during the period. Cynosure Group LLC’s holdings in Repligen were worth $428,000 at the end of the most recent quarter.

Several other institutional investors have also recently modified their holdings of RGEN. Champlain Investment Partners LLC increased its holdings in Repligen by 149.0% in the 3rd quarter. Champlain Investment Partners LLC now owns 1,420,935 shares of the biotechnology company’s stock worth $211,464,000 after buying an additional 850,345 shares during the period. Thrivent Financial for Lutherans grew its holdings in Repligen by 240.5% during the second quarter. Thrivent Financial for Lutherans now owns 601,829 shares of the biotechnology company’s stock worth $75,866,000 after acquiring an additional 425,061 shares during the period. Bank of New York Mellon Corp lifted its stake in shares of Repligen by 21.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 1,370,375 shares of the biotechnology company’s stock valued at $172,749,000 after purchasing an additional 237,884 shares during the period. Conestoga Capital Advisors LLC boosted its stake in shares of Repligen by 26.7% during the 2nd quarter. Conestoga Capital Advisors LLC now owns 946,877 shares of the biotechnology company’s stock worth $119,363,000 after acquiring an additional 199,322 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in Repligen by 39.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 429,524 shares of the biotechnology company’s stock worth $54,149,000 after purchasing an additional 121,305 shares during the period. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Repligen Stock Up 2.2 %

Repligen stock opened at $149.99 on Thursday. The firm has a market capitalization of $8.40 billion, a P/E ratio of -405.37, a P/E/G ratio of 4.40 and a beta of 0.96. The stock’s fifty day simple moving average is $140.74 and its 200-day simple moving average is $142.89. Repligen Co. has a twelve month low of $113.50 and a twelve month high of $211.13. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.34 by $0.09. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The company had revenue of $154.87 million for the quarter, compared to analyst estimates of $153.34 million. During the same quarter last year, the company earned $0.23 EPS. Repligen’s revenue for the quarter was up 9.7% compared to the same quarter last year. As a group, equities analysts expect that Repligen Co. will post 1.52 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Repligen news, Director Anthony Hunt sold 22,191 shares of the firm’s stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the sale, the director now owns 139,840 shares of the company’s stock, valued at approximately $20,328,540.80. This trade represents a 13.70 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 1.20% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities research analysts recently commented on the stock. Benchmark reissued a “hold” rating on shares of Repligen in a report on Monday, August 5th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $205.00 target price on shares of Repligen in a research note on Thursday, September 26th. JPMorgan Chase & Co. upped their price objective on Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a report on Wednesday, July 31st. Wolfe Research initiated coverage on shares of Repligen in a research note on Thursday, November 14th. They set a “peer perform” rating for the company. Finally, StockNews.com raised shares of Repligen from a “sell” rating to a “hold” rating in a research note on Friday, November 22nd. Four research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $190.25.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.